To read the full story, subscribe or sign in.

MAP Gets Boost on Positive Phase III Migraine Study

May 27, 2009

Shares in MAP Pharmaceuticals Inc. spiked 185.7 percent Tuesday on the news that its Phase III migraine study of Levadex hit all four primary objectives. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 16, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Capsules and tablets scattered over a world map

Biopharma tariffs becoming more than a threat

BioWorld

U.S. tariffs on biopharmaceuticals have advanced beyond administration talking points.As a precursor to tariffs, Commerce Secretary Howard Lutnick initiated an...

Kelun Biotech rendering of sacituzumab tirumotecan

Kelun posts phase I/II data of China’s first TROP2 ADC for NSCLC

BioWorld

Phase I/II trial results of sacituzumab tirumotecan (sac-TMT; Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.) published in Nature Medicine came a month after...